echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Ruiyang Pharmaceutical's first review of 1 billion varieties

    Ruiyang Pharmaceutical's first review of 1 billion varieties

    • Last Update: 2022-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      On January 5, the official website of the State Food and Drug Administration showed that Ruiyang Pharmaceutical's 3 types of generic drugs, Roxatidine Hydrochloride Acetate for Injection, were approved for production and deemed to have been reviewed.
    Sexual evaluation

    .
    According to data from Minet.
    com, the sales of this product in China's public medical institutions will be close to 1 billion yuan in 2020, a year-on-year increase of 59.
    6%

    .
     
     
     Source: State Food and Drug Administration official website
     
      Roxatidine hydrochloride acetate is a histamine H2 receptor antagonist, which can effectively inhibit gastric acid secretion.
    It is clinically used for upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.
    ) of low-risk patients

    .
     
      Including Ruiyang Pharmaceutical, there are currently 3 domestic companies that have production approvals for roxatidine hydrochloride acetate for injection.
    According to Minet.
    com data, the product will be used in urban public
    hospitals , county-level public hospitals, urban community centers, and public hospitals in China in 2020.
    The terminal sales of township health centers (referred to as Chinese public medical institutions) are close to 1 billion yuan, a year-on-year increase of 59.
    6%

    .
     
      Development of Consistency Evaluation of Roxatidine Hydrochloride Acetate for Injection
      Source: Minet Consistency Evaluation Database
     
      At present, 3 companies have submitted the marketing application of rosatidine hydrochloride for injection under the new registration classification.
    Among them, the product of Ruiyang Pharmaceutical has been successfully approved, and the first one has passed the consistency evaluation; Sihuan Pharmaceutical has submitted the supplementary application for the consistency of the product , is still under review and approval

    .
     
      Ruiyang Pharmaceutical has reviewed injections
      Source: MED2.
    0 China Drug Evaluation Database
     
      According to the data from Minet.
    com, 19 products of Ruiyang Pharmaceutical have passed or are deemed to have passed the consistency evaluation, including roxatidine hydrochloride acetate for injection, 9 of which are injections

    .
     
      Source: Minet database, the official website of the State Food and Drug Administration, etc.
     
      Note: The statistics are as of January 7th, if there are any omissions, please correct me!
      On January 5, the official website of the State Food and Drug Administration showed that Ruiyang Pharmaceutical's 3 types of generic drugs, Roxatidine Hydrochloride Acetate for Injection, were approved for production and deemed to have been reviewed.
    Sexual evaluation

    .
    According to data from Minet.
    com, the sales of this product in China's public medical institutions will be close to 1 billion yuan in 2020, a year-on-year increase of 59.
    6%

    .
     
     
     Source: State Food and Drug Administration official website
     
      Roxatidine hydrochloride acetate is a histamine H2 receptor antagonist, which can effectively inhibit gastric acid secretion.
    It is clinically used for upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.
    ) of low-risk patients

    .
     
      Including Ruiyang Pharmaceutical, there are currently 3 domestic companies that have production approvals for roxatidine hydrochloride acetate for injection.
    According to Minet.
    com data, the product will be used in urban public
    hospitals , county-level public hospitals, urban community centers, and public hospitals in China in 2020.
    The terminal sales of township health centers (referred to as Chinese public medical institutions) are close to 1 billion yuan, a year-on-year increase of 59.
    6%

    .
     
      Development of Consistency Evaluation of Roxatidine Hydrochloride Acetate for Injection
      Source: Minet Consistency Evaluation Database
     
      At present, 3 companies have submitted the marketing application of rosatidine hydrochloride for injection under the new registration classification.
    Among them, the product of Ruiyang Pharmaceutical has been successfully approved, and the first one has passed the consistency evaluation; Sihuan Pharmaceutical has submitted the supplementary application for the consistency of the product , is still under review and approval

    .
     
      Ruiyang Pharmaceutical has reviewed injections
      Source: MED2.
    0 China Drug Evaluation Database
     
      According to the data from Minet.
    com, 19 products of Ruiyang Pharmaceutical have passed or are deemed to have passed the consistency evaluation, including roxatidine hydrochloride acetate for injection, 9 of which are injections

    .
     
      Source: Minet database, the official website of the State Food and Drug Administration, etc.
     
      Note: The statistics are as of January 7th, if there are any omissions, please correct me!
      On January 5, the official website of the State Food and Drug Administration showed that Ruiyang Pharmaceutical's 3 types of generic drugs, Roxatidine Hydrochloride Acetate for Injection, were approved for production and deemed to have been reviewed.
    Sexual evaluation

    .
    According to data from Minet.
    com, the sales of this product in China's public medical institutions will be close to 1 billion yuan in 2020, a year-on-year increase of 59.
    6%

    .
     
     
     
     Source: State Food and Drug Administration official website
     
     
      Roxatidine hydrochloride acetate is a histamine H2 receptor antagonist, which can effectively inhibit gastric acid secretion.
    It is clinically used for upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.
    ) of low-risk patients

    .
     
      Including Ruiyang Pharmaceutical, there are currently 3 domestic companies that have production approvals for roxatidine hydrochloride acetate for injection.
    According to Minet.
    com data, the product will be used in urban public
    hospitals , county-level public hospitals, urban community centers, and public hospitals in China in 2020.
    The terminal sales of township health centers (referred to as Chinese public medical institutions) are close to 1 billion yuan, a year-on-year increase of 59.
    6%

    .
    Enterprise Enterprise Enterprise Hospital Hospital Hospital
     
      Development of Consistency Evaluation of Roxatidine Hydrochloride Acetate for Injection
      
      Source: Minet Consistency Evaluation Database
     
      At present, 3 companies have submitted the marketing application of rosatidine hydrochloride for injection under the new registration classification.
    Among them, the product of Ruiyang Pharmaceutical has been successfully approved, and the first one has passed the consistency evaluation; Sihuan Pharmaceutical has submitted the supplementary application for the consistency of the product , is still under review and approval

    .
     
      Ruiyang Pharmaceutical has reviewed injections
      
      Source: MED2.
    0 China Drug Evaluation Database
     
      According to the data from Minet.
    com, 19 products of Ruiyang Pharmaceutical have passed or are deemed to have passed the consistency evaluation, including roxatidine hydrochloride acetate for injection, 9 of which are injections

    .
     
      Source: Minet database, the official website of the State Food and Drug Administration, etc.
      Source: Minet database, the official website of the State Food and Drug Administration, etc.
     
      Note: The statistics are as of January 7th, if there are any omissions, please correct me!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.